What happens when you take dabigatran with St. John's wort?
Dabigatran (Pradaxa) is a direct thrombin inhibitor used to prevent strokes in atrial fibrillation and to treat or prevent venous blood clots. It is given as a prodrug, dabigatran etexilate, and depends heavily on the P-glycoprotein (P-gp) transporter system for its absorption. St. John's wort (Hypericum perforatum) is a popular herbal product taken for low mood, and its main active constituent, hyperforin, can switch on P-gp in the gut and liver. When the two are combined over time, the herb's effect on this transporter can nudge dabigatran levels down.
- St. John's wort gradually induces P-gp. With regular use over a couple of weeks, hyperforin increases the amount of P-glycoprotein the body makes in the intestine and liver. This is a slow build-up, not an immediate switch.
- Dabigatran depends on P-gp for absorption. Because dabigatran etexilate is a P-gp substrate, more of this transporter means more of the drug is pumped back out of cells before it can be absorbed and act.
- Dabigatran levels can drift lower. The net result is a modest fall in dabigatran blood concentrations. In human studies the size of this effect has been small, but it points in the direction of slightly less anticoagulant in the bloodstream.
- Anticoagulant protection may be slightly reduced. Lower drug levels mean somewhat weaker thrombin blocking. This is the theoretical concern, even though no real-world clot has been documented from the pairing.
Why is this important?
Dabigatran is prescribed for high-stakes reasons: stroke prevention in atrial fibrillation and the treatment or prevention of deep vein thrombosis and pulmonary embolism. When an anticoagulant works less well, the downside is not a minor side effect, it is the clot the medicine is meant to prevent.
Unlike warfarin, dabigatran does not come with a routine blood test that patients check at home, so a quiet drop in drug levels would not show up on a monitor. That uncertainty is part of why prescribers prefer to avoid combining dabigatran with P-gp inducers like St. John's wort, even though the measured interaction is modest. Dabigatran's official prescribing information warns against P-gp inducers in general, naming rifampin as its example rather than St. John's wort specifically.
The effect is also slow to reverse. After St. John's wort is stopped, it takes roughly one to two weeks for P-gp activity to settle back toward baseline, so there is a window where dosing may need to be reassessed rather than assumed to be back to normal.
What should you do?
Before any change: If you are about to start dabigatran and currently take St. John's wort, tell your prescriber before your first dose so the supplement can be stopped and an alternative considered. If you are already on dabigatran and have been taking St. John's wort, contact your prescriber rather than stopping anything on your own, because the herb's lingering effect means timing matters.
Every day while on both: Do not start or stop St. John's wort on a whim while taking dabigatran. Take your anticoagulant exactly as prescribed and keep using the same products consistently so your prescriber is reasoning about a stable picture. Read supplement labels, since St. John's wort hides in many mood, stress, and sleep blends.
After a change: If St. John's wort is stopped, remember the effect on P-gp fades over a week or two; your prescriber may want to reassess during that window. Throughout, watch for signs of inadequate anticoagulation, such as sudden facial droop, arm weakness, slurred speech, sudden severe headache, chest pain, shortness of breath, or new leg swelling and pain. These can signal stroke, pulmonary embolism, or deep vein thrombosis and need emergency evaluation.
Which specific products are affected?
On the medication side this applies to dabigatran etexilate (Pradaxa) at all strengths. The same induction concern applies in principle to other direct oral anticoagulants that depend on P-gp and/or CYP3A4: apixaban (Eliquis), rivaroxaban (Xarelto), and edoxaban (Savaysa, Lixiana).
On the supplement side this covers St. John's wort capsules, tablets, tinctures, teas, and combination mood or stress products. Look for Hypericum perforatum, hypericin, or hyperforin on labels. Many sleep and anti-anxiety formulas include St. John's wort inside proprietary blends, where it is easy to miss.
The science behind it
Dabigatran's FDA prescribing information warns that P-gp inducers reduce exposure to the drug and should generally be avoided; the label names rifampin as its example rather than St. John's wort specifically. That warning rests on a known mechanism: the strong P-gp inducer rifampin lowered dabigatran exposure by roughly two-thirds (the label reports AUC and Cmax reductions of about 66% and 67%) in the label's probe study, which establishes that P-gp induction can meaningfully affect this drug.
St. John's wort itself is a much weaker inducer than rifampin. Human mechanistic studies have shown St. John's wort raises intestinal P-gp expression several-fold, and the degree of induction depends on the product's hyperforin content, so different brands behave differently. A 2025 systematic review in Clinical Pharmacokinetics that used dabigatran among its P-gp probe drugs classified St. John's wort as, at most, a weak inducer of dabigatran exposure on repeated dosing, with only small overall changes and even transient inhibition reported after a single dose. Importantly, there are no published human thrombosis case reports from the combination. The honest summary is a plausible, modest, direction-consistent effect, not a documented catastrophe.
Frequently Asked Questions
Is taking St. John's wort with dabigatran dangerous?
It is best avoided, but the evidence points to a modest effect rather than a dramatic one. The herb can lower dabigatran levels somewhat over time, and because dabigatran treats serious clotting conditions, prescribers prefer to steer clear. There are no documented clots caused by the pairing.
I took both for a few days. Should I panic?
No. The interaction builds up gradually over a couple of weeks of regular use, so a few days is unlikely to have changed much. Contact your prescriber or pharmacist for advice rather than stopping anything abruptly on your own.
Can I just stop the St. John's wort myself?
Talk to your prescriber first. Stopping the herb is reasonable, but its effect on P-gp lingers for a week or two afterward, so your dosing may need to be reviewed during that period rather than assumed to be immediately back to normal.
Does this apply to other blood thinners?
The same P-gp concern applies in principle to the other direct oral anticoagulants, including apixaban, rivaroxaban, and edoxaban. If you take any of these, treat St. John's wort with the same caution and check with your pharmacist.
What can I take for low mood instead?
Ask your doctor about options that do not induce P-gp, such as standard prescription antidepressants, or non-drug approaches like talking therapy and exercise. Your prescriber can choose something compatible with your anticoagulant.
Could the herb be hidden in a product I already take?
Yes. St. John's wort often appears inside mood, stress, and sleep blends under names like Hypericum perforatum, hypericin, or hyperforin. Check the full ingredient list of any supplement while you are on dabigatran.
Key takeaways
- St. John's wort can modestly induce P-glycoprotein, the transporter dabigatran relies on, which may lower dabigatran levels with regular use.
- The measured effect in human studies is weak, and no thrombosis cases have been reported from the combination, but dabigatran's serious indications make avoidance the prudent choice.
- Dabigatran's FDA label warns against P-gp inducers in general (naming rifampin), and St. John's wort is a known P-gp inducer in this class.
- Do not stop either product abruptly on your own; the herb's effect fades over one to two weeks, so dosing may need reassessment.
- Review any change with your doctor or pharmacist, and seek emergency care for sudden stroke or clot symptoms.